| Drug Name |
Exemestane |
| Drug ID |
BADD_D00861 |
| Description |
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. |
| Indications and Usage |
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. |
| Marketing Status |
approved; investigational |
| ATC Code |
L02BG06 |
| DrugBank ID |
DB00990
|
| KEGG ID |
D00963
|
| MeSH ID |
C056516
|
| PubChem ID |
60198
|
| TTD Drug ID |
D0D2VS
|
| NDC Product Code |
62157-091; 65129-1217; 44278-025; 71921-190; 51552-1619; 65427-030; 68724-1003; 51991-005; 63629-2056; 68382-383; 49386-026; 73377-132; 46439-8746; 59762-2858; 70771-1374; 65162-240; 0054-0080; 69097-316; 59057-007; 64918-0622; 64181-0005; 59651-516; 52128-134; 64918-0621; 53104-7666; 59057-008; 0832-0595; 65089-0046; 0009-7663 |
| UNII |
NY22HMQ4BX
|
| Synonyms |
exemestane | examestane | 6-methyleneandrosta-1,4-diene-3,17-dione | FCE 24304 | FCE-24304 | Aromasil | Aromasin | Aromasine |
